Fixed-Duration Ibrutinib–Venetoclax Versus Chlorambucil–Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (GLOW): 4-Year Follow-Up from a Multicentre, Open-Label, Randomised, Phase III Trial

In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously untreated chronic lymphocytic leukemia who were older or had comorbidities, or both, at a median follow up of 27·7 months.